Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial

This publication has 28 references indexed in Scilit:

• Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
  Gastroenterology, 2015
• Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations
  Gastroenterology, 2014
• Status of non‐steroidal anti‐inflammatory drugs use and its association with chronic kidney disease: A cross‐sectional survey in China
  Nephrology, 2014
• Challenges in the management of acute peptic ulcer bleeding
  The Lancet, 2013
• Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit
  Gut, 2011
• Future Cardiovascular Disease in China
  Circulation: Cardiovascular Quality and Outcomes, 2010
• Celecoxib for the Prevention of Colorectal Adenomatous Polyps
  New England Journal of Medicine, 2006
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Preventing Recurrent Upper Gastrointestinal Bleeding in Patients withHelicobacter pyloriInfection Who Are Taking Low-Dose Aspirin or Naproxen
  New England Journal of Medicine, 2001
• Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
  Proceedings of the National Academy of Sciences, 1999